Login to Your Account

Thrombogenics Files BLA For Ocraplasmin in VMA

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, December 28, 2011
Thrombogenics NV is entering the most crucial year of its existence, with decisions from both the U.S. and European regulators due over the coming months on its filing for ocraplasmin as a treatment for symptomatic vitreomacular adhesion (VMA) including macular hole.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription